Press Releases

Press Releases

Jul 02, 2020
Frank Czworka appointed SVP, Global Sales Brian Webb promoted to SVP, Manufacturing GAITHERSBURG, Md. , July 02, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the...
Jun 29, 2020
GAITHERSBURG, Md. , June 29, 2020 (GLOBE NEWSWIRE) -- Novavax , Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Ben Machielse as Executive Vice President, CMC, with responsibility for...
Jun 24, 2020
GAITHERSBURG, Md. , June 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino , Senior Vice President, Chief Business Officer and Chief Financial...
Jun 17, 2020
Dr. Filip Dubovsky appointed SVP, Chief Medical Officer Silvia Taylor appointed SVP, Investor Relations and Corporate Affairs GAITHERSBURG, Md. , June 17, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious...
Jun 16, 2020
GAITHERSBURG, Md. , June 16, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has appointed David Mott as an independent director to its Board of Directors. Mr....
Jun 15, 2020
GAITHERSBURG, Md. , June 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has entered into an agreement to sell Series A Convertible preferred stock, convertible...
Jun 04, 2020
$60 million funding for manufacturing of NVX-CoV2373 10 million doses to be delivered to DoD in 2020 GAITHERSBURG, Md. , June 04, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
May 27, 2020
Novavax acquires Praha Vaccines in Czech Republic Annual operating capacity of over 1 billion doses of COVID-19 vaccine antigen GAITHERSBURG, Md. , May 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious...
May 25, 2020
First participants enrolled in Phase 1 portion of clinical trial of NVX‑CoV2373 Preliminary immunogenicity and safety results expected in July 2020 Phase 2 portion to begin promptly following successful Phase 1 results GAITHERSBURG, Md. , May 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc....
Displaying 11 - 20 of 180